June 26, 2020
South Korean regulators approved Eisai’s Equfina (safinamide) for the treatment of idiopathic Parkinson’s disease as an add-on to levodopa therapies in patients with end-of-dose motor fluctuations, the company said on June 25. The approval was supported by an overseas PIII...read more